Recombinant human bone morphogenetic protein-2 (rhBMP-2) in the treatment of mandibular sequelae after tumor resection.
BACKGROUND
Ameloblastoma is a locally aggressive tumor most often found in posterior body and angle of the mandible. Although ameloblastoma has histological characteristics of benignity, they have a high percentage of local recurrence and possible malignant development if treated improperly.


METHODS
This report presents a treatment of unusual mandibular sequelae after tumor resection using recombinant human bone morphogenetic protein-2 (rhBMP-2) associated with hydroxyapatite (HA) and calcium triphosphate (TCP).


CONCLUSIONS
Seven months after surgery, the patient was asymptomatic, with stable occlusion and class I, without signs of infection or rejection, and bone repair with rigidity compatible to an immature bone structure was observed. Reconstruction of large mandibular bone defect with a combination of rhBMP-2 and HA/TCP achieving a satisfactory result with less invasive and minimum morbidity has been demonstrated.
Zétola
André
A
Oral Implantology, SOEPAR, R. Prof. Benedito N. Santos, Curitiba, PR, Brazil. alz2009@hotmail.com
Ferreira
Felipe Mussi
FM
Larson
Rafaela
R
Shibli
Jamil Awad
JA
D000328:Adult; D000564:Ameloblastoma / Q000601:surgery*; D001672:Biocompatible Materials / Q000627:therapeutic use; D055396:Bone Morphogenetic Protein 2 / Q000627:therapeutic use*; D001860:Bone Plates / Q000009:adverse effects; D018786:Bone Substitutes / Q000627:therapeutic use; D016025:Bone Transplantation / Q000009:adverse effects; D002130:Calcium Phosphates / Q000627:therapeutic use; D003094:Collagen; D017577:Cutaneous Fistula / Q000209:etiology; D020878:Device Removal; D004337:Drug Carriers; D017886:Durapatite / Q000627:therapeutic use; D004868:Equipment Failure; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008339:Mandibular Neoplasms / Q000601:surgery*; D016155:Oral Fistula / Q000209:etiology; D011994:Recombinant Proteins / Q000627:therapeutic use; D019651:Plastic Surgery Procedures / Q000379:methods*; D013526:Surgical Mesh; D013529:Surgical Wound Dehiscence / Q000209:etiology / Q000601:surgery*; D013530:Surgical Wound Infection / Q000209:etiology / Q000601:surgery*; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*
D001672:Biocompatible Materials; D055396:Bone Morphogenetic Protein 2; D018786:Bone Substitutes; D002130:Calcium Phosphates; D004337:Drug Carriers; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D003094:Collagen; D017886:Durapatite; C018392:tricalcium phosphate